Clinical Trial Update: Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Sacituzumab Govitecan to Docetaxel in advanced or metastatic non-small cell lung cancer has results posted as of 2025-01-14.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Gilead Sciences | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-01-14